Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine Er to fesoterodine: post-hoc analysis from an observational and retrospective study
BMC Urology, 07/27/2012
Castro–Diaz D et al. – A change from tolterodine extended–release therapy to fesoterodine with dose escalation to 8 mg in symptomatic overactive Bladder patients, seems to be associated with greater improvement in terms of both patient–reported–treatment benefit and clinical global impression of change. Improvement was not affected by age.